nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfinpyrazone—ABCC3—Cyclosporine—psoriasis	0.097	0.0988	CbGbCtD
Sulfinpyrazone—CYP2C8—Tazarotene—psoriasis	0.0757	0.0771	CbGbCtD
Sulfinpyrazone—ABCC1—Cyclosporine—psoriasis	0.0596	0.0607	CbGbCtD
Sulfinpyrazone—ABCC2—Mycophenolate mofetil—psoriasis	0.0582	0.0593	CbGbCtD
Sulfinpyrazone—ABCC3—Methotrexate—psoriasis	0.0514	0.0523	CbGbCtD
Sulfinpyrazone—ABCC2—Cyclosporine—psoriasis	0.0441	0.0449	CbGbCtD
Sulfinpyrazone—CYP2B6—Cholecalciferol—psoriasis	0.0427	0.0435	CbGbCtD
Sulfinpyrazone—ABCC4—Methotrexate—psoriasis	0.0392	0.04	CbGbCtD
Sulfinpyrazone—CYP2C8—Cholecalciferol—psoriasis	0.0323	0.0329	CbGbCtD
Sulfinpyrazone—ABCC1—Methotrexate—psoriasis	0.0315	0.0321	CbGbCtD
Sulfinpyrazone—ABCC2—Dexamethasone—psoriasis	0.029	0.0296	CbGbCtD
Sulfinpyrazone—CYP2C8—Mycophenolate mofetil—psoriasis	0.028	0.0285	CbGbCtD
Sulfinpyrazone—CYP3A4—Calcitriol—psoriasis	0.0254	0.0259	CbGbCtD
Sulfinpyrazone—ABCC2—Methotrexate—psoriasis	0.0233	0.0238	CbGbCtD
Sulfinpyrazone—CYP2C9—Cholecalciferol—psoriasis	0.0225	0.023	CbGbCtD
Sulfinpyrazone—CYP2C8—Hydrocortisone—psoriasis	0.0225	0.0229	CbGbCtD
Sulfinpyrazone—CYP2C8—Cyclosporine—psoriasis	0.0212	0.0216	CbGbCtD
Sulfinpyrazone—CYP3A4—Methoxsalen—psoriasis	0.0198	0.0202	CbGbCtD
Sulfinpyrazone—ABCB1—Mycophenolate mofetil—psoriasis	0.019	0.0193	CbGbCtD
Sulfinpyrazone—CYP2B6—Dexamethasone—psoriasis	0.0185	0.0188	CbGbCtD
Sulfinpyrazone—ABCB1—Betamethasone—psoriasis	0.0163	0.0166	CbGbCtD
Sulfinpyrazone—ABCB1—Prednisolone—psoriasis	0.0161	0.0164	CbGbCtD
Sulfinpyrazone—ABCB1—Hydrocortisone—psoriasis	0.0152	0.0155	CbGbCtD
Sulfinpyrazone—ABCB1—Prednisone—psoriasis	0.0152	0.0154	CbGbCtD
Sulfinpyrazone—CYP2C9—Cyclosporine—psoriasis	0.0148	0.0151	CbGbCtD
Sulfinpyrazone—ABCB1—Cyclosporine—psoriasis	0.0144	0.0146	CbGbCtD
Sulfinpyrazone—CYP2C8—Dexamethasone—psoriasis	0.014	0.0142	CbGbCtD
Sulfinpyrazone—CYP3A4—Cholecalciferol—psoriasis	0.0131	0.0134	CbGbCtD
Sulfinpyrazone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0114	0.0116	CbGbCtD
Sulfinpyrazone—CYP3A4—Triamcinolone—psoriasis	0.0114	0.0116	CbGbCtD
Sulfinpyrazone—CYP2C9—Dexamethasone—psoriasis	0.00976	0.00993	CbGbCtD
Sulfinpyrazone—CYP3A4—Betamethasone—psoriasis	0.00975	0.00993	CbGbCtD
Sulfinpyrazone—CYP3A4—Prednisolone—psoriasis	0.00962	0.0098	CbGbCtD
Sulfinpyrazone—ABCB1—Dexamethasone—psoriasis	0.00947	0.00964	CbGbCtD
Sulfinpyrazone—CYP3A4—Hydrocortisone—psoriasis	0.00912	0.00929	CbGbCtD
Sulfinpyrazone—CYP3A4—Prednisone—psoriasis	0.00909	0.00925	CbGbCtD
Sulfinpyrazone—CYP3A4—Cyclosporine—psoriasis	0.00861	0.00877	CbGbCtD
Sulfinpyrazone—ABCB1—Methotrexate—psoriasis	0.00761	0.00775	CbGbCtD
Sulfinpyrazone—CYP3A4—Dexamethasone—psoriasis	0.00567	0.00578	CbGbCtD
Sulfinpyrazone—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00119	0.0658	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00101	0.0557	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000819	0.0454	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.000737	0.0408	CbGpPWpGaD
Sulfinpyrazone—SLC22A12—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000699	0.0387	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000624	0.0346	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000508	0.0281	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000484	0.0268	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000455	0.0252	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—IL22—psoriasis	0.000436	0.0242	CbGpPWpGaD
Sulfinpyrazone—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000384	0.0213	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000335	0.0185	CbGpPWpGaD
Sulfinpyrazone—SLC22A12—SLC-mediated transmembrane transport—CP—psoriasis	0.000318	0.0176	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000306	0.0169	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000302	0.0167	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000278	0.0154	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000259	0.0143	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000256	0.0142	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000248	0.0137	CbGpPWpGaD
Sulfinpyrazone—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00022	0.0122	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000211	0.0117	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00021	0.0116	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000208	0.0115	CbGpPWpGaD
Sulfinpyrazone—ABCC5—NRF2 pathway—TGFA—psoriasis	0.000197	0.0109	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000194	0.0107	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Hemostasis—SERPINB8—psoriasis	0.000189	0.0105	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00018	0.01	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000171	0.00947	CbGpPWpGaD
Sulfinpyrazone—SLC22A12—Transmembrane transport of small molecules—CP—psoriasis	0.000161	0.00895	CbGpPWpGaD
Sulfinpyrazone—SLC22A12—Transmembrane transport of small molecules—CARM1—psoriasis	0.000154	0.00853	CbGpPWpGaD
Sulfinpyrazone—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000154	0.00851	CbGpPWpGaD
Sulfinpyrazone—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.00015	0.0083	CbGpPWpGaD
Sulfinpyrazone—ABCC3—NRF2 pathway—TGFA—psoriasis	0.000145	0.00804	CbGpPWpGaD
Sulfinpyrazone—ABCC6—Transmembrane transport of small molecules—CP—psoriasis	0.000144	0.00797	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000141	0.00778	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000139	0.0077	CbGpPWpGaD
Sulfinpyrazone—ABCC6—Transmembrane transport of small molecules—CARM1—psoriasis	0.000137	0.00761	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000137	0.0076	CbGpPWpGaD
Sulfinpyrazone—ABCC4—NRF2 pathway—TGFA—psoriasis	0.000136	0.00756	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000132	0.0073	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.00013	0.0072	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Fluoropyrimidine Activity—TP53—psoriasis	0.000126	0.00698	CbGpPWpGaD
Sulfinpyrazone—ABCC2—NRF2 pathway—TGFA—psoriasis	0.000115	0.00637	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000113	0.00624	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000112	0.00618	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000111	0.00616	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.00011	0.00609	CbGpPWpGaD
Sulfinpyrazone—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000107	0.00593	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000104	0.00574	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.8e-05	0.00543	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.68e-05	0.00536	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Fluoropyrimidine Activity—TP53—psoriasis	9.29e-05	0.00515	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	9.08e-05	0.00503	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	8.95e-05	0.00496	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Fluoropyrimidine Activity—TP53—psoriasis	8.74e-05	0.00484	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—HLA-C—psoriasis	8.26e-05	0.00458	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—IL13—psoriasis	8.21e-05	0.00455	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—IL17A—psoriasis	7.56e-05	0.00419	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.22e-05	0.004	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Metabolism—NDUFA5—psoriasis	7.11e-05	0.00394	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—IL12B—psoriasis	7.02e-05	0.00389	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—HLA-E—psoriasis	6.86e-05	0.0038	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.75e-05	0.00374	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Transmembrane transport of small molecules—CP—psoriasis	6.61e-05	0.00366	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.38e-05	0.00354	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Transmembrane transport of small molecules—CARM1—psoriasis	6.3e-05	0.00349	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Metabolism—CYP2S1—psoriasis	6.05e-05	0.00335	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.99e-05	0.00332	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.9e-05	0.00327	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Platelet degranulation—VEGFA—psoriasis	5.69e-05	0.00315	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	5.67e-05	0.00314	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Hemostasis—ITGAL—psoriasis	5.48e-05	0.00304	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	5.42e-05	0.00301	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism—NDUFA5—psoriasis	5.24e-05	0.0029	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.16e-05	0.00286	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—IL10—psoriasis	5.14e-05	0.00285	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—IL4—psoriasis	5e-05	0.00277	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.89e-05	0.00271	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.88e-05	0.00271	CbGpPWpGaD
Sulfinpyrazone—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.88e-05	0.0027	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	4.87e-05	0.0027	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	4.65e-05	0.00257	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Transmembrane transport of small molecules—CP—psoriasis	4.58e-05	0.00254	CbGpPWpGaD
Sulfinpyrazone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	4.55e-05	0.00252	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—HLA-A—psoriasis	4.53e-05	0.00251	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism—CYP2S1—psoriasis	4.46e-05	0.00247	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.45e-05	0.00247	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Transmembrane transport of small molecules—CARM1—psoriasis	4.37e-05	0.00242	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4.14e-05	0.00229	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism—NDUFA5—psoriasis	4.11e-05	0.00228	CbGpPWpGaD
Sulfinpyrazone—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	3.86e-05	0.00214	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.83e-05	0.00212	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	3.82e-05	0.00211	CbGpPWpGaD
Sulfinpyrazone—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	3.68e-05	0.00204	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	3.64e-05	0.00202	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism—CYP2S1—psoriasis	3.49e-05	0.00193	CbGpPWpGaD
Sulfinpyrazone—ABCC6—dermis—psoriasis	3.23e-05	0.807	CbGeAlD
Sulfinpyrazone—ABCB1—Allograft Rejection—IFNG—psoriasis	3.02e-05	0.00167	CbGpPWpGaD
Sulfinpyrazone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.01e-05	0.00167	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Metabolism—CARM1—psoriasis	2.95e-05	0.00164	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.81e-05	0.00156	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Metabolism—NDUFA5—psoriasis	2.65e-05	0.00147	CbGpPWpGaD
Sulfinpyrazone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.63e-05	0.00146	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.53e-05	0.0014	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.34e-05	0.00129	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.31e-05	0.00128	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.28e-05	0.00126	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Metabolism—CYP2S1—psoriasis	2.25e-05	0.00125	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Hemostasis—NOS2—psoriasis	2.25e-05	0.00125	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism—NDUFA5—psoriasis	2.24e-05	0.00124	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism—CARM1—psoriasis	2.18e-05	0.00121	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.09e-05	0.00116	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.03e-05	0.00113	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Allograft Rejection—TNF—psoriasis	1.95e-05	0.00108	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Metabolism—NDUFA5—psoriasis	1.95e-05	0.00108	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.94e-05	0.00108	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism—CYP2S1—psoriasis	1.91e-05	0.00106	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.83e-05	0.00101	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism—NDUFA5—psoriasis	1.83e-05	0.00101	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Metabolism—CAT—psoriasis	1.82e-05	0.00101	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.82e-05	0.00101	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Disease—HLA-A—psoriasis	1.8e-05	0.001	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.73e-05	0.00096	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism—CARM1—psoriasis	1.71e-05	0.000945	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.7e-05	0.000943	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Disease—APOE—psoriasis	1.68e-05	0.000933	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Metabolism—CYP2S1—psoriasis	1.66e-05	0.00092	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.59e-05	0.000883	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Disease—NOS2—psoriasis	1.57e-05	0.00087	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism—CYP2S1—psoriasis	1.55e-05	0.00086	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Metabolism—APOE—psoriasis	1.41e-05	0.000782	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism—CAT—psoriasis	1.34e-05	0.000742	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Hemostasis—VEGFA—psoriasis	1.3e-05	0.000721	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.29e-05	0.000714	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Disease—TYK2—psoriasis	1.29e-05	0.000712	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.24e-05	0.000687	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Metabolism—PPARG—psoriasis	1.23e-05	0.000681	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.2e-05	0.000667	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Disease—CD4—psoriasis	1.16e-05	0.000644	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.13e-05	0.000624	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Metabolism—CARM1—psoriasis	1.1e-05	0.000609	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism—CAT—psoriasis	1.05e-05	0.000581	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Disease—HLA-A—psoriasis	1.04e-05	0.000578	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism—APOE—psoriasis	1.04e-05	0.000576	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.02e-05	0.000567	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.99e-06	0.000554	CbGpPWpGaD
Sulfinpyrazone—ABCC4—Hemostasis—TP53—psoriasis	9.84e-06	0.000545	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Disease—APOE—psoriasis	9.73e-06	0.000539	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	9.65e-06	0.000534	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism—CARM1—psoriasis	9.31e-06	0.000516	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Disease—NOS2—psoriasis	9.07e-06	0.000502	CbGpPWpGaD
Sulfinpyrazone—ABCC3—Metabolism—PPARG—psoriasis	9.06e-06	0.000502	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Disease—STAT3—psoriasis	9e-06	0.000499	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.71e-06	0.000482	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	8.5e-06	0.000471	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism—APOE—psoriasis	8.15e-06	0.000452	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.13e-06	0.000451	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Metabolism—CARM1—psoriasis	8.11e-06	0.00045	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism—CARM1—psoriasis	7.58e-06	0.00042	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Disease—TYK2—psoriasis	7.43e-06	0.000412	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Metabolism—PPARG—psoriasis	7.1e-06	0.000393	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.09e-06	0.000393	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Metabolism—CAT—psoriasis	6.77e-06	0.000375	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Disease—CD4—psoriasis	6.72e-06	0.000372	CbGpPWpGaD
Sulfinpyrazone—ABCC5—Disease—IL6—psoriasis	6.29e-06	0.000348	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism—CAT—psoriasis	5.73e-06	0.000317	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Metabolism—APOE—psoriasis	5.26e-06	0.000291	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Disease—STAT3—psoriasis	5.2e-06	0.000288	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Metabolism—CARM1—psoriasis	5e-06	0.000277	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Metabolism—CAT—psoriasis	4.99e-06	0.000276	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism—CAT—psoriasis	4.66e-06	0.000258	CbGpPWpGaD
Sulfinpyrazone—CYP2B6—Metabolism—PPARG—psoriasis	4.58e-06	0.000254	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism—APOE—psoriasis	4.45e-06	0.000247	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Metabolism—APOE—psoriasis	3.88e-06	0.000215	CbGpPWpGaD
Sulfinpyrazone—CYP2C8—Metabolism—PPARG—psoriasis	3.88e-06	0.000215	CbGpPWpGaD
Sulfinpyrazone—ABCC1—Disease—IL6—psoriasis	3.63e-06	0.000201	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism—APOE—psoriasis	3.62e-06	0.000201	CbGpPWpGaD
Sulfinpyrazone—ABCB1—Metabolism—PPARG—psoriasis	3.38e-06	0.000187	CbGpPWpGaD
Sulfinpyrazone—CYP2C9—Metabolism—PPARG—psoriasis	3.16e-06	0.000175	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Metabolism—CAT—psoriasis	3.07e-06	0.00017	CbGpPWpGaD
Sulfinpyrazone—CYP3A4—Metabolism—APOE—psoriasis	2.39e-06	0.000132	CbGpPWpGaD
Sulfinpyrazone—ABCC5—tendon—psoriasis	2.18e-06	0.0544	CbGeAlD
Sulfinpyrazone—CYP3A4—Metabolism—PPARG—psoriasis	2.08e-06	0.000115	CbGpPWpGaD
Sulfinpyrazone—ABCC4—tendon—psoriasis	1.51e-06	0.0377	CbGeAlD
Sulfinpyrazone—ABCC2—tendon—psoriasis	1.46e-06	0.0365	CbGeAlD
Sulfinpyrazone—CYP2B6—skin of body—psoriasis	1.29e-06	0.0323	CbGeAlD
Sulfinpyrazone—ABCC1—tendon—psoriasis	1.29e-06	0.0322	CbGeAlD
